Geron (GERN) Projected to Release Earnings on Wednesday

Geron (NASDAQ:GERN) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Geron to post earnings of ($0.01) per share and revenue of $55.3030 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The firm had revenue of $51.84 million during the quarter, compared to analyst estimates of $50.59 million. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. On average, analysts expect Geron to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Price Performance

Shares of GERN opened at $1.29 on Monday. The stock has a market cap of $827.56 million, a price-to-earnings ratio of -11.73 and a beta of 0.61. The company has a quick ratio of 4.96, a current ratio of 6.78 and a debt-to-equity ratio of 0.52. Geron has a 12 month low of $1.04 and a 12 month high of $2.01. The company has a 50-day moving average price of $1.32 and a two-hundred day moving average price of $1.46.

Institutional Investors Weigh In On Geron

A number of hedge funds have recently added to or reduced their stakes in GERN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Geron by 2.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after acquiring an additional 8,123 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Geron by 12.0% during the second quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 9,849 shares in the last quarter. Velan Capital Investment Management LP lifted its position in shares of Geron by 14.3% during the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 10,000 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Geron by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 456,176 shares of the biopharmaceutical company’s stock valued at $625,000 after purchasing an additional 15,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Geron by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 316,622 shares of the biopharmaceutical company’s stock valued at $446,000 after purchasing an additional 18,491 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Geron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.00.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.